280
19. Duchene D, Cavalli R, Gref R (2016)
Cyclodextrin-based polymeric nanoparticles
as efficient carriers for anticancer drugs. Curr
Pharm Biotechnol 17(3):248–255
20. Daga M, Ullio C, Argenziano M et al (2017)
Drug delivery nanoparticles in treating chemoresistant tumor cells. Curr Med Chem
24(42):4800–4815
21. Osmani AM, Hani UR, Bhosale R et al (2017)
Nanosponge carriers—an archetype swing in
cancer therapy: a comprehensive review. Curr
Drug Targets 18(1):108–118
22. Peimanfard S, Caldera F, Pedrazzo AR
et al (2018) Smart cyclodextrin-based drug
delivery
systems:
stimuli-responsiveness
and controlled release. Biomed J Sci Tech
Res
9(5).
https://doi.org/10.26717/
BJSTR.2018.09.001850
23. Mognetti B, Barberis A, Marino S et al (2012)
In vitro enhancement of anticancer activity of
paclitaxel by a Cremophor free cyclodextrinbased nanosponge formulation. J Incl
Phenom Macrocycl Chem 74(1–4):201–210
24. Castiglione F, Crupi V, Majolino D et al
(2013) Vibrational dynamics and hydrogen
bond properties of β-CD nanosponges: an
FTIR-ATR, Raman and solid-state NMR
spectroscopic study. J Incl Phenom Macrocycl
Chem 75(3–4):247–254
25. Ansari AK, Torne J, Vavia S et al (2011)
Paclitaxel loaded nanosponges: in-vitro
characterization and cytotoxicity study on
MCF-7 cell line culture. Curr Drug Deliv
8(2):194–202
26. Torne SJ, Ansari KA, Vavia PR et al (2010)
Enhanced oral paclitaxel bioavailability after
administration of paclitaxel-loaded. Drug
Deliv 17(6):419–425
27. Swaminathan S, Pastero L, Serpe L et al
(2010) Cyclodextrin-based Nanosponges
encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity.
Eur J Pharm Biopharm 74(2):193–201
28. Minelli R, Cavalli R, Ellis L et al (2012)
Nanosponge-encapsulated
camptothecin
exerts anti-tumor activity in human prostate
cancer cells. Eur J Pharm Sci 47(4):686–694
29. Gigliotti CL, Minelli R, Cavalli R et al (2016)
In vitro and in vivo therapeutic evaluation of
Camptothecin-encapsulated b-Cyclodextrin
Nanosponges in prostate Cancer. J Biomed
Nanotechnol 12(1):114–127
30. Gigliotti CL, Ferrara B, Occhipinti S et al
(2017) Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid
cancer cells in vitro and in vivo on orthotopic
xenograft tumors. Drug Deliv 24(1):670–680
31. Torne S, Darandale S, Vavia P et al (2013)
Cyclodextrin-based nanosponges: effective
nanocarrier for tamoxifen delivery. Pharm
Dev Technol 18(3):619–625
32. Friedman HS, Kerby T, Calvert H (2000)
Temozolomide and treatment of malignant
glioma. Clin Cancer Res 6(7):2585–2597
33. Jain D, Gursalkar T, Bajaj A (2013)
Nanosponges of an anticancer agent for
potential treatment of brain tumors. Am J
Neuroprot Neuroregen 5:32–43
34. Darandale SS, Vavia PR (2013) Cyclodextrinbased nanosponges of curcumin: formulation
and physicochemical characterization. J Incl
Phenom Macrocycl Chem 75(3–4):315–322
35. Huillard O, Boissier E, Blanchet B et al
(2014) Drug safety evaluation of sorafenib for
treatment of solid tumors: consequences for
the risk assessment and management of cancer
patients. Expert Opin Drug Saf 13:663–673
36. Giglio V, Viale M, Bertone V et al (2018)
Cyclodextrin polymers as nanocarriers for
sorafenib. Investig New Drugs 36(3):370–379
37. Gigliotti CL, Boggio E, Clemente N et al
(2016) ICOS-ligand triggering impairs osteoclast differentiation and function in vitro and
in vivo. J Immunol 197:3905–3916
38. Argenziano M, Dianzani C, Ferrara B et al
(2019) β-Cyclodextrin nanosponges for
enabling ICOS antitumor effect. In: Advances
in drug delivery and biomaterials: facts and
vision, Padova, 2019. Pharmaceutics. https://
doi.org/10.3390/pharmaceutics11010048
39. Trotta F, Rossi B, Venuti V et al (2015)
Toward an understanding of the thermosensitive behaviour of pH-responsive hydrogels based on cyclodextrins. Soft Matter
11(29):5862–5871
40. Lo Meo P, Russo M, Saladino ML et al
(2016)
Polyaminocyclodextrin
nanosponges: synthesis, characterization and pHresponsive sequestration abilities. RSC Adv
6(55):49941–49953
41. Jones DP, Carlson JL, Samiec PS et al (1998)
Glutathione measurement in human plasma:
evaluation of sample collection, storage and
derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta
275(2):175–184
42. Trotta F, Caldera F, Dianzani C et al (2016)
Glutathione bioresponsive cyclodextrin nanosponges. ChemPlusChem 81(5):439–443
43. Pizzimenti S, Trotta F, Barrera G et al
(2016) GSH-targeted nanosponges increase
doxorubicin- induced toxicity “in vitro” and
“in vivo” in cancer cells with high antioxidant
defenses. Free Radic Biol Med 97:24–37
44. Mayzlish-Gati E, Laufer D, Grivas CF et al
(2015) Strigolactone analogs act as new
anti-cancer agents in inhibition of breast cancer in xenograft model. Cancer Biol Ther
16(11):1682–1688
45. Argenziano M, Lombardi C, Ferrara B
et al (2018) Glutathione/pH-responsive
nanosponges enhance strigolactone delivMaria Tannous et al.
19. Duchene D, Cavalli R, Gref R (2016)
Cyclodextrin-based polymeric nanoparticles
as efficient carriers for anticancer drugs. Curr
Pharm Biotechnol 17(3):248–255
20. Daga M, Ullio C, Argenziano M et al (2017)
Drug delivery nanoparticles in treating chemoresistant tumor cells. Curr Med Chem
24(42):4800–4815
21. Osmani AM, Hani UR, Bhosale R et al (2017)
Nanosponge carriers—an archetype swing in
cancer therapy: a comprehensive review. Curr
Drug Targets 18(1):108–118
22. Peimanfard S, Caldera F, Pedrazzo AR
et al (2018) Smart cyclodextrin-based drug
delivery
systems:
stimuli-responsiveness
and controlled release. Biomed J Sci Tech
Res
9(5).
https://doi.org/10.26717/
BJSTR.2018.09.001850
23. Mognetti B, Barberis A, Marino S et al (2012)
In vitro enhancement of anticancer activity of
paclitaxel by a Cremophor free cyclodextrinbased nanosponge formulation. J Incl
Phenom Macrocycl Chem 74(1–4):201–210
24. Castiglione F, Crupi V, Majolino D et al
(2013) Vibrational dynamics and hydrogen
bond properties of β-CD nanosponges: an
FTIR-ATR, Raman and solid-state NMR
spectroscopic study. J Incl Phenom Macrocycl
Chem 75(3–4):247–254
25. Ansari AK, Torne J, Vavia S et al (2011)
Paclitaxel loaded nanosponges: in-vitro
characterization and cytotoxicity study on
MCF-7 cell line culture. Curr Drug Deliv
8(2):194–202
26. Torne SJ, Ansari KA, Vavia PR et al (2010)
Enhanced oral paclitaxel bioavailability after
administration of paclitaxel-loaded. Drug
Deliv 17(6):419–425
27. Swaminathan S, Pastero L, Serpe L et al
(2010) Cyclodextrin-based Nanosponges
encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity.
Eur J Pharm Biopharm 74(2):193–201
28. Minelli R, Cavalli R, Ellis L et al (2012)
Nanosponge-encapsulated
camptothecin
exerts anti-tumor activity in human prostate
cancer cells. Eur J Pharm Sci 47(4):686–694
29. Gigliotti CL, Minelli R, Cavalli R et al (2016)
In vitro and in vivo therapeutic evaluation of
Camptothecin-encapsulated b-Cyclodextrin
Nanosponges in prostate Cancer. J Biomed
Nanotechnol 12(1):114–127
30. Gigliotti CL, Ferrara B, Occhipinti S et al
(2017) Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid
cancer cells in vitro and in vivo on orthotopic
xenograft tumors. Drug Deliv 24(1):670–680
31. Torne S, Darandale S, Vavia P et al (2013)
Cyclodextrin-based nanosponges: effective
nanocarrier for tamoxifen delivery. Pharm
Dev Technol 18(3):619–625
32. Friedman HS, Kerby T, Calvert H (2000)
Temozolomide and treatment of malignant
glioma. Clin Cancer Res 6(7):2585–2597
33. Jain D, Gursalkar T, Bajaj A (2013)
Nanosponges of an anticancer agent for
potential treatment of brain tumors. Am J
Neuroprot Neuroregen 5:32–43
34. Darandale SS, Vavia PR (2013) Cyclodextrinbased nanosponges of curcumin: formulation
and physicochemical characterization. J Incl
Phenom Macrocycl Chem 75(3–4):315–322
35. Huillard O, Boissier E, Blanchet B et al
(2014) Drug safety evaluation of sorafenib for
treatment of solid tumors: consequences for
the risk assessment and management of cancer
patients. Expert Opin Drug Saf 13:663–673
36. Giglio V, Viale M, Bertone V et al (2018)
Cyclodextrin polymers as nanocarriers for
sorafenib. Investig New Drugs 36(3):370–379
37. Gigliotti CL, Boggio E, Clemente N et al
(2016) ICOS-ligand triggering impairs osteoclast differentiation and function in vitro and
in vivo. J Immunol 197:3905–3916
38. Argenziano M, Dianzani C, Ferrara B et al
(2019) β-Cyclodextrin nanosponges for
enabling ICOS antitumor effect. In: Advances
in drug delivery and biomaterials: facts and
vision, Padova, 2019. Pharmaceutics. https://
doi.org/10.3390/pharmaceutics11010048
39. Trotta F, Rossi B, Venuti V et al (2015)
Toward an understanding of the thermosensitive behaviour of pH-responsive hydrogels based on cyclodextrins. Soft Matter
11(29):5862–5871
40. Lo Meo P, Russo M, Saladino ML et al
(2016)
Polyaminocyclodextrin
nanosponges: synthesis, characterization and pHresponsive sequestration abilities. RSC Adv
6(55):49941–49953
41. Jones DP, Carlson JL, Samiec PS et al (1998)
Glutathione measurement in human plasma:
evaluation of sample collection, storage and
derivatization conditions for analysis of dansyl derivatives by HPLC. Clin Chim Acta
275(2):175–184
42. Trotta F, Caldera F, Dianzani C et al (2016)
Glutathione bioresponsive cyclodextrin nanosponges. ChemPlusChem 81(5):439–443
43. Pizzimenti S, Trotta F, Barrera G et al
(2016) GSH-targeted nanosponges increase
doxorubicin- induced toxicity “in vitro” and
“in vivo” in cancer cells with high antioxidant
defenses. Free Radic Biol Med 97:24–37
44. Mayzlish-Gati E, Laufer D, Grivas CF et al
(2015) Strigolactone analogs act as new
anti-cancer agents in inhibition of breast cancer in xenograft model. Cancer Biol Ther
16(11):1682–1688
45. Argenziano M, Lombardi C, Ferrara B
et al (2018) Glutathione/pH-responsive
nanosponges enhance strigolactone delivMaria Tannous et al.